Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01- Clinical Trial Not Allowed)

The summary for the Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01- Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01- Clinical Trial Not Allowed): The objective of the Molecular Atlas of Lung Development (LungMAP) program is to build a comprehensive molecular and cellular atlas of the human lung to serve as a reference platform to better understand both normal biology and disease pathobiology, and to identify critical cellular components, molecular pathways, and novel therapeutic targets in lung disease. LungMAP is an open access resource integrating multi-scale, high-content, high-resolution information to define lung cells with gene expression, physiological states, 3-dimensional locations, as well as developmental and pathological trajectories.

Federal Grant Title:	Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01- Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-24-015
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.838
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 27th, 2023
Original Application Deadline:	October 27th, 2023
Posted Date:	September 6th, 2023
Creation Date:	September 6th, 2023
Archive Date:	December 2nd, 2023
Total Program Funding:
Maximum Federal Grant Award:	$300,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	September 6th, 2023

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See full Notice of Funding Opportunity for additional details on eligibility.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-24-015.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Limited Competition: Physician Scientist Transition to Independence in Blood Science Resea...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordi...; • Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clin...; • Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical T...; • Pathogenesis of Sars Lung Disease: in Vitro Studies and Animal Models; • Lung Response to Inhaled Highly Toxic Chemicals; • Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01)
More Grants from the National Institutes of Health: • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...; • Cellular Models of HIV Pathogenesis within NIDDK Mission Areas (R01 Clinical Trial Not All...; • U.S.-South Africa Program for Collaborative Biomedical Research Phase 3 (HIV/AIDS) (R01 C...; • Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Option...; • Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional)